Try our beta test site

Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease (ASPIRE)

This study has been terminated.
Advanced Biosciences Research
Information provided by (Responsible Party):
Cardium Therapeutics Identifier:
First received: February 29, 2012
Last updated: September 27, 2016
Last verified: September 2016

February 29, 2012
September 27, 2016
March 2012
May 2016   (Final data collection date for primary outcome measure)
Change in reversible perfusion defect size (RPDS) as measured by adenosine triphosphate (ATP) single-photon emission computed tomography with technetium-99m sestamibi (SPECT) [ Time Frame: Baseline and Week 8 ]
Same as current
Complete list of historical versions of study NCT01550614 on Archive Site
  • Change in angina frequency and nitroglycerin use [ Time Frame: Baseline and Week 8 ]
  • Change in quality of life using the Seattle Angina Questionnaire [ Time Frame: Baseline and Week 8 ]
  • Change in patient functional class using CCS anginal classification [ Time Frame: Baseline and Week 8 ]
  • Safety of Ad5FGF-4 as assessed by adverse events and clinical laboratory testing [ Time Frame: Through Week 8 ]
  • Long-term safety of Ad5FGF-4 as assessed by serious adverse events [ Time Frame: Through Month 12 ]
Same as current
Not Provided
Not Provided
Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease
A Randomized, Controlled, Parallel Group, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Ad5FGF-4 Using SPECT Myocardial Perfusion Imaging in Patients With Stable Angina Pectoris
The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4, delivered during induced transient ischemia, is effective in improving myocardial perfusion, angina functional class, patient symptoms, and quality of life. Short-term (8 weeks) and long-term (12 month) safety of Ad5FGF-4 will also be evaluated. The primary endpoint is change in adenosine triphosphate (ATP) stress SPECT reperfusion defect size.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Angina, Stable
Genetic: Alferminogene tadenovec
One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)
Other Names:
  • Generx
  • Cardionovo (Russian Trade Name)
  • Experimental: Arm A: Ad5FGF-4
    Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer and standard of care angina medication
    Intervention: Genetic: Alferminogene tadenovec
  • No Intervention: Arm B
    Standard of care angina medication

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
May 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients 18-75 years of age, inclusive
  • Postmenopausal female patients, women of childbearing potential and men willing to use an effective contraception method while on the study treatment and/or who agree not to become pregnant or make their partner pregnant throughout the study and during one year after administration of the study drug
  • Female subjects of childbearing potential who have a negative urine pregnancy test, and are willing to use an acceptable form of birth control during the study
  • Diagnostic coronary angiogram in the past confirming the presence of coronary artery disease. Patients with extensive disease, or high risk for intervention, or who don't want the higher risk angioplasty or surgery, or have had angioplasty with recurrent angina and vessels are not ideal for angioplasty are ideal candidates
  • Stable angina pectoris being treated with chronic anti-anginal medication(s) at a stable dose for 2 weeks prior to randomization
  • Left ventricular ejection fraction (LVEF) of ≥30%. If the LVEF is <30% the patient can be enrolled if there is no recent or current congestive heart failure present
  • Evidence of stress induced myocardial ischemia by ATP technetium-99m sestamibi SPECT, defined as a reversible perfusion defect size of ≥9%
  • Willing and able to comply with the study requirements
  • Provided written informed consent

Exclusion Criteria:

  • Female patients who are pregnant, lactating (breast milk feeding), or planning a pregnancy during the course of the study and one year after administration of the study drug. Women of child bearing potential who are not using an acceptable method of birth control. Women of child bearing potential with a positive urine pregnancy test within 24 hours prior to the start of investigational product
  • Patients with unstable angina for whom an immediate revascularization procedure is indicated
  • Patients for whom a cardiac revascularization procedure is planned in the next 3 months
  • Myocardial infarction within the 3 months prior to the Screening visit
  • Congestive heart failure NYHA Class IV
  • Myocarditis or restrictive pericarditis
  • Left main coronary stenosis ≥70% (unless the patient has a patent graft or collateral vessels supplying the left coronary circulation) or proximal stenoses ≥70% in all major coronary conduit vessels (coronary arteries and bypass grafts)
  • A single patent coronary conduit (for example, totally occluded RCA and LCx with no bypass grafts. Patient will not tolerate balloon occlusion of the LAD for infusion)
  • Clinically significant aortic or mitral valvular heart disease.
  • Life threatening coronary ostial stenosis that precludes adequate catheter engagement in any target vessel, unless the vessel can be accessed via a patent bypass graft
  • Coronary artery to venous communications, which bypass the coronary capillary bed
  • Untreated life-threatening ventricular arrhythmias
  • Uncontrolled arterial hypertension with systolic blood pressure >180 mm Hg and diastolic pressure >100 mm Hg
  • CABG surgery within the past 6 months, unless those grafts are now occluded
  • Percutaneous transluminal coronary angioplasty (PTCA) within the past 3 months, unless the stented/dilated vessel(s) are now occluded
  • Enhanced external counterpulsation (EECP) within 3 months prior to the start of screening evaluations
  • Transmyocardial or percutaneous myocardial laser revascularization within the previous year
  • Prior treatment with any cardiovascular gene therapy
  • Patients who received an investigational drug or biologic within 30 days of screening or are currently participating in an investigational drug, biologic or device trial
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Russian Federation
Not Provided
Not Provided
Cardium Therapeutics
Cardium Therapeutics
Advanced Biosciences Research
Study Director: Gabor Rubanyi Cardium Therapeutics
Cardium Therapeutics
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP